Comparative Pharmacology
Head-to-head clinical analysis: LIOTHYRONINE SODIUM versus THYROLAR 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIOTHYRONINE SODIUM versus THYROLAR 3.
LIOTHYRONINE SODIUM vs THYROLAR-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liothyronine is a synthetic form of triiodothyronine (T3), the active thyroid hormone. It binds to thyroid hormone receptors in the nucleus, modulating gene transcription and increasing basal metabolic rate, oxygen consumption, and thermogenesis. It enhances carbohydrate and lipid metabolism, and promotes normal growth and development.
THYROLAR-3 is a combination of synthetic T4 (levothyroxine) and T3 (liothyronine) that replaces or supplements endogenous thyroid hormones. T4 is converted to the active T3 in peripheral tissues. Thyroid hormones bind to thyroid hormone receptors (TRα and TRβ), regulating gene transcription involved in metabolism, growth, and development.
25-75 mcg orally once daily; initial dose 25 mcg daily, titrate by 12.5-25 mcg increments every 1-2 weeks based on response.
Adults: Initial dose 30 mg orally once daily; adjust based on thyroid function tests. Typical maintenance dose 60-120 mg once daily.
None Documented
None Documented
Approximately 1-2 days in euthyroid patients; shorter in hyperthyroidism, prolonged in hypothyroidism. Clinical context: requires monitoring of thyroid function tests for dose adjustment.
Levothyroxine (T4): 6-7 days; Liothyronine (T3): 1-2 days. Clinical context: In hyperthyroidism, half-life shortened; in hypothyroidism, prolonged.
Primarily renal (approximately 50% as unchanged drug and metabolites); minor biliary/fecal elimination.
Renal (approximately 50% as unchanged drug and conjugates); fecal (~20%); biliary (~10%)
Category A/B
Category C
Thyroid Hormone
Thyroid Hormone